Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met

Journal of the Neurological Sciences

Volumn 284, Issue 1-2, 2009, Pages 158-162

  Dardiotis, Efthimios ^a,b   Koutsou, Pantelitsa ^a   Zamba Papanicolaou, Eleni ^a   Vonta, Ilia ^c   Hadjivassiliou, Marilena ^a   Hadjigeorgiou, Georgios ^b   Cariolou, Marios ^a   Christodoulou, Kyproula ^a   Kyriakides, Theodoros ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^c UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Familial amyloidotic neuropathy; Modifier genes; Transthyretin; TTR Val30Met

Indexed keywords

CHAPERONE; COMPLEMENT COMPONENT C1Q; PREALBUMIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYPRUS; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GREECE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE OF ONSET; AGED; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; APOLIPOPROTEIN E2; COMPLEMENT C1Q; CYPRUS; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; GREECE; HUMANS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREALBUMIN; SERUM AMYLOID P-COMPONENT;

EID: 67849088532     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.05.018     Document Type: Article

References (38)

1. Plante-Bordeneuve V., and Said G. Transthyretin related familial amyloid polyneuropathy. Curr Opin Neurol 13 (2000) 569-573
2. Hou X., Aguilar M.I., and Small D.H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. Febs J 274 (2007) 1637-1650
3. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75 (1952) 408-427
4. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 590 (1976) 1-64
5. Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol 9 (1996) 355-359
6. Conceicao I., and De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35 (2007) 116-118
7. Holmgren G., Costa P.M., Andersson C., Asplund K., Steen L., Beckman L., et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 31 (1994) 351-354
8. Dardiotis E., Koutsou P., Papanicolaou E.Z., Vonta I., Kladi A., Vassilopoulos D., et al. Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 16 (2009) 32-37
9. Sousa A., Coelho T., Barros J., and Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 60 (1995) 512-521
10. Soares M.L., Coelho T., Sousa A., Batalov S., Conceicao I., Sales-Luis M.L., et al. Susceptibility and modifier genes in Portuguese transthyretin V30 M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet 14 (2005) 543-553
11. Sousa A., Andersson R., Drugge U., Holmgren G., and Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 43 (1993) 288-294
12. Koike H., Misu K., Ikeda S., Ando Y., Nakazato M., Ando E., et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59 (2002) 1771-1776
13. Benson M.D., and Kincaid J.C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36 (2007) 411-423
14. Westermark P., Sletten K., Johansson B., and Cornwell III G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 87 (1990) 2843-2845
15. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., and Brito R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276 (2001) 27207-27213
16. Hammarstrom P., Schneider F., and Kelly J.W. Trans-suppression of misfolding in an amyloid disease. Science 293 (2001) 2459-2462
17. Wisniewski T., and Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135 (1992) 235-238
18. Yi S., Takahashi K., Naito M., Tashiro F., Wakasugi S., Maeda S., et al. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol 138 (1991) 403-412
19. Hafer-Macko C.E., Dyck P.J., and Koski C.L. Complement activation in acquired and hereditary amyloid neuropathy. J Peripher Nerv Syst 5 (2000) 131-139
20. Murakami T., Yi S., Maeda S., Tashiro F., Yamamura K., Takahashi K., et al. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Am J Pathol 141 (1992) 451-456
21. Satoh S., Tokuda T., Ikeda S., Sekijima Y., Yanagisawa N., Hidaka H., et al. No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy. Neurosci Lett 204 (1996) 209-211
22. Tennent G.A., Lovat L.B., and Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92 (1995) 4299-4303
23. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002) 254-259
24. Cariolou M.A., Kokkofitou A., Manoli P., Christou S., Karagrigoriou A., and Middleton L. Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Genet Epidemiol 12 (1995) 489-497
25. Perneger T.V. What's wrong with Bonferroni adjustments. Bmj 316 (1998) 1236-1238
26. Sousa M.M., and Saraiva M.J. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71 (2003) 385-400
27. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., and Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159 (2001) 1993-2000
28. Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 10 Suppl 1 (2003) 7-12
29. Soares M.L., Coelho T., Sousa A., Holmgren G., Saraiva M.J., Kastner D.L., et al. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30 M) in Portugal and Sweden. Eur J Hum Genet 12 (2004) 225-237
30. Racila D.M., Sontheimer C.J., Sheffield A., Wisnieski J.J., Racila E., and Sontheimer R.D. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 12 (2003) 124-132
31. Racila E., Racila D.M., Ritchie J.M., Taylor C., Dahle C., and Weiner G.J. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 58 (2006) 1-8
32. Webster S.D., Tenner A.J., Poulos T.L., and Cribbs D.H. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol Aging 20 (1999) 297-304
33. Fonseca M.I., Zhou J., Botto M., and Tenner A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 24 (2004) 6457-6465
34. Tenner A.J., and Fonseca M.I. The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. Adv Exp Med Biol 586 (2006) 153-176
35. Pisalyaput K., and Tenner A.J. Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem 104 (2008) 696-707
36. Talbot C., Lendon C., Craddock N., Shears S., Morris J.C., and Goate A. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 343 (1994) 1432-1433
37. Greenberg S.M., Vonsattel J.P., Segal A.Z., Chiu R.I., Clatworthy A.E., Liao A., Hyman B.T., and Rebeck G.W. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50 (1998) 961-965
38. Saunders A.M., Schmader K., Breitner J.C., Benson M.D., Brown W.T., Goldfarb L., Goldgaber D., Manwaring M.G., Szymanski M.H., McCown N., et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342 (1993) 710-711